51
|
Yang S, Zhao J, Chen Y, Lei M. Biomarkers Associated with Ischemic Stroke in Diabetes Mellitus Patients. Cardiovasc Toxicol 2017; 16:213-22. [PMID: 26175178 DOI: 10.1007/s12012-015-9329-8] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Diabetes is an established risk factor for ischemic stroke, but the associated molecular mechanisms remain to be fully elucidated. This study investigated the role of plasma and platelet microRNAs and their targeting proteins in the activation of platelets and their association with the occurrence of ischemic stroke in patients with type 2 diabetes mellitus (T2DM). Results showed that the expressions of platelet and plasma miR-144 and miR-223 were significantly altered in T2DM patients with or without ischemic stroke compared to that in healthy controls, but these changes were more significant in T2DM patients with ischemic stroke. The expressions of P2Y12 and IRS-1 as well as phosphorylation levels of IRS-1, PI3K, and Akt in platelets were significantly altered in T2DM patients with or without ischemic stroke. The expression of platelet miR-144 and miR-223 significantly correlated with their plasma levels, P2Y12 and IRS-1 expression, blood glucose concentration, and platelet activation rate. High glucose concentration significantly elevated P-selectin, miR-144 and P2Y12 expression and significantly reduced miR-223 and IRS-1 expression in UT-7 cells. Overexpression of miR-223 and blocking of miR-144 expression significantly normalized the effects of high glucose concentration in UT-7 cells. In conclusion, hyperglycemia may activate platelets through miR-144 and miR-223 to downregulate IRS-1 and upregulate P2Y12 expression in the platelets of T2DM patients through an IRS-1-PI3K-Akt signaling. Low platelet and plasma miR-223 expression in addition to high platelet and plasma miR-144 expression are risk factors for ischemic stroke in T2DM patients.
Collapse
Affiliation(s)
- Shuisheng Yang
- Department of Endocrinology, Xiangya Hospital, Central South University, Xiangya Road 87, Changsha, 410008, People's Republic of China
| | - Jingfeng Zhao
- Hepatobiliary Enteric Surgery Research Center, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China
| | - Yuxiang Chen
- Hepatobiliary Enteric Surgery Research Center, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China.
| | - Minxiang Lei
- Department of Endocrinology, Xiangya Hospital, Central South University, Xiangya Road 87, Changsha, 410008, People's Republic of China.
| |
Collapse
|
52
|
Chandran R, Mehta SL, Vemuganti R. Non-coding RNAs and neuroprotection after acute CNS injuries. Neurochem Int 2017; 111:12-22. [PMID: 28131900 DOI: 10.1016/j.neuint.2017.01.015] [Citation(s) in RCA: 88] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2016] [Revised: 01/17/2017] [Accepted: 01/24/2017] [Indexed: 02/07/2023]
Abstract
Accumulating evidence indicates that various classes of non-coding RNAs (ncRNAs) including microRNAs (miRNAs), PIWI-interacting RNAs (piRNAs) and long non-coding RNAs (lncRNAs) play important roles in normal state as well as the diseases of the CNS. Interestingly, ncRNAs have been shown to interact with messenger RNA, DNA and proteins, and these interactions could induce epigenetic modifications and control transcription and translation, thereby adding a new layer of genomic regulation. The ncRNA expression profiles are known to be altered after acute CNS injuries including stroke, traumatic brain injury and spinal cord injury that are major contributors of morbidity and mortality worldwide. Hence, a better understanding of the functional significance of ncRNAs following CNS injuries could help in developing potential therapeutic strategies to minimize the neuronal damage in those conditions. The potential of ncRNAs in blood and CSF as biomarkers for diagnosis and/or prognosis of acute CNS injuries has also gained importance in the recent years. This review highlighted the current progress in the understanding of the role of ncRNAs in initiation and progression of secondary neuronal damage and their application as biomarkers after acute CNS injuries.
Collapse
Affiliation(s)
- Raghavendar Chandran
- Department of Neurological Surgery, University of Wisconsin-Madison and William S. Middleton Veterans Hospital, Madison, WI, USA
| | - Suresh L Mehta
- Department of Neurological Surgery, University of Wisconsin-Madison and William S. Middleton Veterans Hospital, Madison, WI, USA
| | - Raghu Vemuganti
- Department of Neurological Surgery, University of Wisconsin-Madison and William S. Middleton Veterans Hospital, Madison, WI, USA.
| |
Collapse
|
53
|
|
54
|
Fejes Z, Póliska S, Czimmerer Z, Káplár M, Penyige A, Gál Szabó G, Beke Debreceni I, Kunapuli SP, Kappelmayer J, Nagy B. Hyperglycaemia suppresses microRNA expression in platelets to increase P2RY12 and SELP levels in type 2 diabetes mellitus. Thromb Haemost 2016; 117:529-542. [PMID: 27975100 DOI: 10.1160/th16-04-0322] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2016] [Accepted: 11/26/2016] [Indexed: 12/19/2022]
Abstract
Megakaryocyte (MK)-derived miRNAs have been detected in platelets. Here, we analysed the expression of platelet and circulating miR-223, miR-26b, miR-126 and miR-140 that might be altered with their target mRNAs in type 2 diabetes mellitus (DM2). MiRNAs were isolated from leukocyte-depleted platelets and plasma samples obtained from 28 obese DM2, 19 non-DM obese and 23 healthy individuals. The effect of hyperglycaemia on miRNAs was also evaluated in MKs using MEG-01 and K562 cells under hyperglycaemic conditions after 8 hours up to four weeks. Quantitation of mature miRNA, pre-miRNAs and target mRNA levels (P2RY12 and SELP) were measured by RT-qPCR. To prove the association of miR-26b and miR-140 with SELP (P-selectin) mRNA level, overexpression or inhibition of these miRNAs in MEG-01 MKs was performed using mimics or anti-miRNAs, respectively. The contribution of calpain substrate Dicer to modulation of miRNAs was studied by calpain inhibition. Platelet activation was evaluated via surface P-selectin by flow cytometry. Mature and pre-forms of investigated miRNAs were significantly reduced in DM2, and platelet P2RY12 and SELP mRNA levels were elevated by two-fold at increased platelet activation compared to controls. Significantly blunted miRNA expressions were observed by hyperglycaemia in MEG-01 and K562-MK cells versus baseline values, while the manipulation of miR-26b and miR-140 expression affected SELP mRNA level. Calpeptin pretreatment restored miRNA levels in hyperglycaemic MKs. Overall, miR-223, miR-26b, miR-126 and miR-140 are expressed at a lower level in platelets and MKs in DM2 causing upregulation of P2RY12 and SELP mRNAs that may contribute to adverse platelet function.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Béla Nagy
- Béla Nagy Jr, MD, PhD, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98. H-4032, Debrecen, Hungary, Tel.: +36 52 340 006, Fax: +36 52 417 631, E-mail:
| |
Collapse
|
55
|
Platelets miRNA as a Prediction Marker of Thrombotic Episodes. DISEASE MARKERS 2016; 2016:2872507. [PMID: 28042196 PMCID: PMC5155104 DOI: 10.1155/2016/2872507] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/25/2016] [Accepted: 10/04/2016] [Indexed: 11/18/2022]
Abstract
The blood platelets are crucial for the coagulation physiology to maintain haemostatic balance and are involved in various pathologies such as atherosclerosis and thrombosis. The studies of recent years have shown that anucleated platelets are able to succeed protein synthesis. Additionally, mRNA translation in blood platelets is regulated by miRNA molecules. Recent works postulate the possibility of using miRNAs as biomarkers of atherosclerosis and ischemic episodes. This review article describes clinical studies that presented blood platelets miRNAs expression profile changes in different thrombotic states, which suggest use of these molecules as predictive biomarkers.
Collapse
|
56
|
Jones Buie JN, Goodwin AJ, Cook JA, Halushka PV, Fan H. The role of miRNAs in cardiovascular disease risk factors. Atherosclerosis 2016; 254:271-281. [PMID: 27693002 PMCID: PMC5125538 DOI: 10.1016/j.atherosclerosis.2016.09.067] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2016] [Revised: 08/31/2016] [Accepted: 09/22/2016] [Indexed: 12/12/2022]
Abstract
Coronary artery disease and atherosclerosis are complex pathologies that develop over time due to genetic and environmental factors. Differential expression of miRNAs has been identified in patients with coronary artery disease and atherosclerosis, however, their association with cardiovascular disease risk factors, including hyperlipidemia, hypertension, obesity, diabetes, lack of physical activity and smoking, remains unclear. This review examines the role of miRNAs as either biomarkers or potential contributors to the pathophysiology of these aforementioned risk factors. It is intended to provide an overview of the published literature which describes alterations in miRNA levels in both human and animal studies of cardiovascular risk factors and when known, the possible mechanism by which these miRNAs may exert either beneficial or deleterious effects. The intent of this review is engage clinical, translational, and basic scientists to design future collaborative studies to further elucidate the potential role of miRNAs in cardiovascular diseases.
Collapse
Affiliation(s)
- Joy N Jones Buie
- Medical University of South Carolina, Department of Pathology and Laboratory Medicine, 173 Ashley Avenue, Suite CRI 605B, Charleston, United States.
| | - Andrew J Goodwin
- Medical University of South Carolina, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Charleston, United States
| | - James A Cook
- Medical University of South Carolina, Department of Neurosciences, Charleston, United States
| | - Perry V Halushka
- Medical University of South Carolina, Department of Pharmacology, Charleston, United States
| | - Hongkuan Fan
- Medical University of South Carolina, Department of Pathology and Laboratory Medicine, 173 Ashley Avenue, Suite CRI 605B, Charleston, United States
| |
Collapse
|
57
|
Kim J, Choi GH, Ko KH, Kim JO, Oh SH, Park YS, Kim OJ, Kim NK. Association of the Single Nucleotide Polymorphisms in microRNAs 130b, 200b, and 495 with Ischemic Stroke Susceptibility and Post-Stroke Mortality. PLoS One 2016; 11:e0162519. [PMID: 27603512 PMCID: PMC5014326 DOI: 10.1371/journal.pone.0162519] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2016] [Accepted: 08/24/2016] [Indexed: 01/26/2023] Open
Abstract
The microRNA (miRNA) is a small non-coding RNA molecule that modulates gene expression at the posttranscriptional level. Platelets have a crucial role in both hemostasis and thrombosis, a condition that can occlude a cerebral artery and cause ischemic stroke. miR-130b, miR-200b, and miR-495 are potential genetic modulators involving platelet production and activation. We hypothesized that single nucleotide polymorphisms (SNPs) in these miRNAs might potentially contribute to the susceptibility to ischemic stroke and post-stroke mortality. This study included 523 ischemic stroke patients and 400 control subjects. We investigated the association of three miRNA SNPs (miR-130bT>C, miR-200bT>C, and miR-495A>C) with ischemic stroke prevalence and post-stroke mortality. In the multivariate logistic regression, there was no statistically significant difference in the distribution of miR-130bT>C, miR-200bT>C, or miR-495A>C between the ischemic stroke and control groups. In the subgroup analysis based on ischemic stroke subtype, the miR-200b CC genotype was less frequently found in the large-artery atherosclerosis stroke subtype compared with controls (TT+CT vs CC; adjusted odds ratio for CC, 0.506; 95% confidence interval, 0.265-0.965). During a mean follow-up period of 4.80 ± 2.11 years after stroke onset, there were 106 all-cause deaths among the 523 stroke patients. Multivariate Cox regression analysis did not find a significant association between post-stroke mortality and three miRNA SNPs. Our findings suggest that the functional SNP of miR-200b might be responsible for the susceptibility to large-artery atherosclerotic stroke.
Collapse
Affiliation(s)
- Jinkwon Kim
- Department of Neurology, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam-si, 13496, South Korea
| | - Gun Ho Choi
- Institute for Clinical Research, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam-si, 13496, South Korea
| | - Ki Han Ko
- Institute for Clinical Research, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam-si, 13496, South Korea
| | - Jung Oh Kim
- Institute for Clinical Research, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam-si, 13496, South Korea
| | - Seung Hun Oh
- Department of Neurology, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam-si, 13496, South Korea
| | - Young Seok Park
- Department of Neurosurgery, Chungbuk National University Hospital, Chungbuk National University, Cheongju-si, 28644, South Korea
| | - Ok Joon Kim
- Department of Neurology, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam-si, 13496, South Korea
- * E-mail: (NKK); (OJK)
| | - Nam Keun Kim
- Institute for Clinical Research, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam-si, 13496, South Korea
- Department of Biomedical Science, College of Life Science, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, 13488, South Korea
- * E-mail: (NKK); (OJK)
| |
Collapse
|
58
|
Du G, Lin Q, Wang J. A brief review on the mechanisms of aspirin resistance. Int J Cardiol 2016; 220:21-6. [PMID: 27372038 DOI: 10.1016/j.ijcard.2016.06.104] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Revised: 06/16/2016] [Accepted: 06/21/2016] [Indexed: 01/08/2023]
Abstract
Aspirin is the most widely prescribed drug for the primary and secondary prevention of cardiovascular and cerebrovascular diseases. However, a large number of patients continue to experience thromboembolic events despite aspirin therapy, a phenomenon referred to as aspirin resistance or treatment failure. Aspirin resistance is often observed along with a high incidence of unstable plaque, cardiovascular events and cerebrovascular accident. Studies have shown that aspirin reduces the production of TXA2, but not totally inhibits the activation of platelets. In this review, we analyze current and past research on aspirin resistance, presenting important summaries of results regarding the potential contributive roles of single nucleotide polymorphisms, inflammation, metabolic syndrome and miRNAs. The aim of this article is to provide a brief review on aspirin resistance and platelet function, which will provide important insights into the research of aspirin resistance.
Collapse
Affiliation(s)
- Gang Du
- Department of Cardiology, The First Affiliated Hospital of Jinan University, Guangzhou, China; Center for Health Informatics and Bioinformatics, New York University School of Medicine, New York, NY, USA
| | - Qiang Lin
- Department of Rehabilitation, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | - Jinhua Wang
- Center for Health Informatics and Bioinformatics, New York University School of Medicine, New York, NY, USA; Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA; Departments of Pediatrics, New York University School of Medicine, New York, NY 10016, USA.
| |
Collapse
|
59
|
Expression of miRNA-26a in platelets is associated with clopidogrel resistance following coronary stenting. Exp Ther Med 2016; 12:518-524. [PMID: 27347088 DOI: 10.3892/etm.2016.3278] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2015] [Accepted: 03/08/2016] [Indexed: 12/27/2022] Open
Abstract
The present study aimed to evaluate the association between platelet microRNA (miRNA)-26a expression and clopidogrel resistance in patients who underwent coronary stenting. Between September 2013 and August 2014, 43 patients with coronary heart disease underwent percutaneous coronary intervention at Heibei General Hospital (Shijiazhuang, China). In the same period, 20 healthy volunteers without any history of cardiovascular disease were enrolled in the present study as the control group. Flow cytometry was used to measure the phosphorylation levels of vasodilator-stimulated phosphoprotein (VASP), and to calculate the platelet reactivity index (PRI). Low response to clopidogrel was defined as PRI ≥50% on day 7 following clopidogrel administration. Western blotting was used to measure protein expression of VASP and reverse transcription-quantitative polymerase chain reaction analysis was performed to determine the expression levels of mRNA and miRNAs. Bioinformatics tools were employed to predict that miR-26a, miR-199 and miR-23a may target VASP mRNA. The results of the present study demonstrated that the activity of platelets in patients with low or high clopidogrel response was increased, as compared with healthy subjects. No differences in platelet VASP protein expression levels were detected between patients with high clopidogrel response and healthy subjects; whereas VASP protein expression was elevated in patients with low clopidogrel response. Furthermore VASP gene transcription was maintained at low levels in healthy subjects and patients with high clopidogrel response, whereas patients with low clopidogrel response exhibited increased VASP mRNA expression levels. Platelet expression of miRNA-26a, but not miRNA-199 or miRNA-23a, was associated with high platelet reactivity. Serum miRNA-26a, miRNA-199 and miRNA-23a were not demonstrated to be involved in clopidogrel resistance. Therefore, the present study demonstrated that platelet miRNA-26a has an important role in clopidogrel resistance. Combined miRNA and VASP PRI tests may aid the early diagnosis and prediction of clopidogrel resistance.
Collapse
|
60
|
Yang ZB, Li TB, Zhang Z, Ren KD, Zheng ZF, Peng J, Luo XJ. The Diagnostic Value of Circulating Brain-specific MicroRNAs for Ischemic Stroke. Intern Med 2016; 55:1279-86. [PMID: 27181533 DOI: 10.2169/internalmedicine.55.5925] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Objective Circulating microRNAs have been recognized as promising biomarkers for various diseases. The aim of the present study was to explore the potential role of circulating miR-107, miR-128b and miR-153 as non-invasive biomarkers in the diagnosis of ischemia stroke. Methods One hundred and fourteen ischemic stroke patients (61±11.3 years old) and 58 healthy volunteers (56±3.9 years old) matched for age and sex were enrolled in this study. Total RNA was isolated from plasma with TRIzol reagent. The circulating microRNAs levels were measured by quantitative real-time polymerase chain reaction. Results The circulating levels of miR-107, miR-128b and miR-153 significantly increased 2.78-, 2.13- and 1.83-fold in ischemia stroke patients in comparison to the healthy volunteers, respectively. Receiver operating characteristic (ROC) curves were analyzed using the SPSS software program and revealed the areas under the curve for circulating miR-107, miR-128b and miR-153 to be 0.97, 0.903 and 0.893 in ischemia stroke patients in comparison to healthy volunteers, respectively. The levels of circulating miR-107, miR-128b and miR-153 therefore positively correlated with the severity of stroke as defined by NIHSS classes. Conclusion Our results suggest that circulating miR-107, miR-128b and miR-153 might be used as potential novel non-invasive biomarkers for the diagnosis of ischemia stroke. However, future prospective trials in large-sized patient cohorts are needed before drawing any definitive conclusions.
Collapse
Affiliation(s)
- Zhong-Bao Yang
- Department of Laboratory Medicine, Xiangya School of Medicine, Central South University, China
| | | | | | | | | | | | | |
Collapse
|
61
|
Faruq O, Vecchione A. microRNA: Diagnostic Perspective. Front Med (Lausanne) 2015; 2:51. [PMID: 26284247 PMCID: PMC4523054 DOI: 10.3389/fmed.2015.00051] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Accepted: 07/17/2015] [Indexed: 12/15/2022] Open
Abstract
Biomarkers are biological measures of a biological state. An ideal marker should be safe and easy to measure, cost efficient, modifiable with treatment, and consistent across gender and ethnic groups. To date, none of the available biomarkers satisfy all of these criteria. In addition, the major limitations of these markers are low specificity, sensitivity, and false positive results. Recently identified, microRNAs (miRNAs) are endogenous, evolutionarily conserved small non-coding RNA (about 22–25 nt long), also known as micro-coordinators of gene expression, which have been shown to be an effective tools to study the biology of diseases and to have great potential as novel diagnostic and prognostic biomarkers with high specificity and sensitivity. In fact, it has been demonstrated that miRNAs play a pivotal role in the regulation of a wide range of developmental and physiological processes and their deficiencies have been related to a number of disease. In addition, miRNAs are stable and can be easily isolated and measured from tissues and body fluids. In this review, we provide a perspective on emerging concepts and potential usefulness of miRNAs as diagnostic markers, emphasizing the involvement of specific miRNAs in particular tumor types, subtypes, cardiovascular diseases, diabetes, infectious diseases, and forensic test.
Collapse
Affiliation(s)
- Omar Faruq
- Division of Pathology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Ospedale Santo Andrea, Sapienza University of Rome , Rome , Italy
| | - Andrea Vecchione
- Division of Pathology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Ospedale Santo Andrea, Sapienza University of Rome , Rome , Italy
| |
Collapse
|
62
|
Elgheznawy A, Shi L, Hu J, Wittig I, Laban H, Pircher J, Mann A, Provost P, Randriamboavonjy V, Fleming I. Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes. Circ Res 2015; 117:157-65. [PMID: 25944670 DOI: 10.1161/circresaha.117.305784] [Citation(s) in RCA: 75] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/04/2014] [Accepted: 05/05/2015] [Indexed: 12/13/2022]
Abstract
RATIONALE MicroRNAs (miRNAs) are short noncoding RNA species generated by the processing of longer precursors by the ribonucleases Drosha and Dicer. Platelets contain large amounts of miRNA that are altered by disease, in particular diabetes mellitus. OBJECTIVE This study determined why platelet miRNA levels are attenuated in diabetic individuals and how decreased levels of the platelet-enriched miRNA, miR-223, affect platelet function. METHODS AND RESULTS Dicer levels were altered in platelets from diabetic mice and patients, a change that could be attributed to the cleavage of the enzyme by calpain, resulting in loss of function. Diabetes mellitus in human subjects as well as in mice resulted in decreased levels of platelet miR-142, miR-143, miR-155, and miR-223. Focusing on only 1 of these miRNAs, miR-223 deletion in mice resulted in modestly enhanced platelet aggregation, the formation of large thrombi and delayed clot retraction compared with wild-type littermates. A similar dysregulation was detected in platelets from diabetic patients. Proteomic analysis of platelets from miR-223 knockout mice revealed increased levels of several proteins, including kindlin-3 and coagulation factor XIII-A. Whereas, kindlin-3 was indirectly regulated by miR-223, factor XIII was a direct target and both proteins were also altered in diabetic platelets. Treating diabetic mice with a calpain inhibitor prevented loss of platelet dicer as well as the diabetes mellitus-induced decrease in platelet miRNA levels and the upregulation of miR-223 target proteins. CONCLUSIONS Thus, calpain inhibition may be one means of normalizing platelet miRNA processing as well as platelet function in diabetes mellitus.
Collapse
Affiliation(s)
- Amro Elgheznawy
- From the Institute for Vascular Signaling, Centre for Molecular Medicine, and DZHK (German Centre for Cardiovascular Research) partner site Rhine-Main, Frankfurt, Germany (A.E., L.S., J.H., H.L., V.R., I.F.); Functional Proteomics, SFB 815 Core Unit, Goethe-University, Frankfurt, Germany (I.W.); Walter-Brendel-Centre of Experimental Medicine and DZHK partner site Munich Heart Alliance, Ludwig-Maximilians-Universität, Munich, Germany (J.P.); Endokrinologikum Frankfurt, Frankfurt, Germany (A.M.); and Centre Hospitalier Universitaire de Québec Research Center, and Faculty of Medicine, Université Laval, Quebec, Canada (P.P.)
| | - Lei Shi
- From the Institute for Vascular Signaling, Centre for Molecular Medicine, and DZHK (German Centre for Cardiovascular Research) partner site Rhine-Main, Frankfurt, Germany (A.E., L.S., J.H., H.L., V.R., I.F.); Functional Proteomics, SFB 815 Core Unit, Goethe-University, Frankfurt, Germany (I.W.); Walter-Brendel-Centre of Experimental Medicine and DZHK partner site Munich Heart Alliance, Ludwig-Maximilians-Universität, Munich, Germany (J.P.); Endokrinologikum Frankfurt, Frankfurt, Germany (A.M.); and Centre Hospitalier Universitaire de Québec Research Center, and Faculty of Medicine, Université Laval, Quebec, Canada (P.P.)
| | - Jiong Hu
- From the Institute for Vascular Signaling, Centre for Molecular Medicine, and DZHK (German Centre for Cardiovascular Research) partner site Rhine-Main, Frankfurt, Germany (A.E., L.S., J.H., H.L., V.R., I.F.); Functional Proteomics, SFB 815 Core Unit, Goethe-University, Frankfurt, Germany (I.W.); Walter-Brendel-Centre of Experimental Medicine and DZHK partner site Munich Heart Alliance, Ludwig-Maximilians-Universität, Munich, Germany (J.P.); Endokrinologikum Frankfurt, Frankfurt, Germany (A.M.); and Centre Hospitalier Universitaire de Québec Research Center, and Faculty of Medicine, Université Laval, Quebec, Canada (P.P.)
| | - Ilka Wittig
- From the Institute for Vascular Signaling, Centre for Molecular Medicine, and DZHK (German Centre for Cardiovascular Research) partner site Rhine-Main, Frankfurt, Germany (A.E., L.S., J.H., H.L., V.R., I.F.); Functional Proteomics, SFB 815 Core Unit, Goethe-University, Frankfurt, Germany (I.W.); Walter-Brendel-Centre of Experimental Medicine and DZHK partner site Munich Heart Alliance, Ludwig-Maximilians-Universität, Munich, Germany (J.P.); Endokrinologikum Frankfurt, Frankfurt, Germany (A.M.); and Centre Hospitalier Universitaire de Québec Research Center, and Faculty of Medicine, Université Laval, Quebec, Canada (P.P.)
| | - Hebatullah Laban
- From the Institute for Vascular Signaling, Centre for Molecular Medicine, and DZHK (German Centre for Cardiovascular Research) partner site Rhine-Main, Frankfurt, Germany (A.E., L.S., J.H., H.L., V.R., I.F.); Functional Proteomics, SFB 815 Core Unit, Goethe-University, Frankfurt, Germany (I.W.); Walter-Brendel-Centre of Experimental Medicine and DZHK partner site Munich Heart Alliance, Ludwig-Maximilians-Universität, Munich, Germany (J.P.); Endokrinologikum Frankfurt, Frankfurt, Germany (A.M.); and Centre Hospitalier Universitaire de Québec Research Center, and Faculty of Medicine, Université Laval, Quebec, Canada (P.P.)
| | - Joachim Pircher
- From the Institute for Vascular Signaling, Centre for Molecular Medicine, and DZHK (German Centre for Cardiovascular Research) partner site Rhine-Main, Frankfurt, Germany (A.E., L.S., J.H., H.L., V.R., I.F.); Functional Proteomics, SFB 815 Core Unit, Goethe-University, Frankfurt, Germany (I.W.); Walter-Brendel-Centre of Experimental Medicine and DZHK partner site Munich Heart Alliance, Ludwig-Maximilians-Universität, Munich, Germany (J.P.); Endokrinologikum Frankfurt, Frankfurt, Germany (A.M.); and Centre Hospitalier Universitaire de Québec Research Center, and Faculty of Medicine, Université Laval, Quebec, Canada (P.P.)
| | - Alexander Mann
- From the Institute for Vascular Signaling, Centre for Molecular Medicine, and DZHK (German Centre for Cardiovascular Research) partner site Rhine-Main, Frankfurt, Germany (A.E., L.S., J.H., H.L., V.R., I.F.); Functional Proteomics, SFB 815 Core Unit, Goethe-University, Frankfurt, Germany (I.W.); Walter-Brendel-Centre of Experimental Medicine and DZHK partner site Munich Heart Alliance, Ludwig-Maximilians-Universität, Munich, Germany (J.P.); Endokrinologikum Frankfurt, Frankfurt, Germany (A.M.); and Centre Hospitalier Universitaire de Québec Research Center, and Faculty of Medicine, Université Laval, Quebec, Canada (P.P.)
| | - Patrick Provost
- From the Institute for Vascular Signaling, Centre for Molecular Medicine, and DZHK (German Centre for Cardiovascular Research) partner site Rhine-Main, Frankfurt, Germany (A.E., L.S., J.H., H.L., V.R., I.F.); Functional Proteomics, SFB 815 Core Unit, Goethe-University, Frankfurt, Germany (I.W.); Walter-Brendel-Centre of Experimental Medicine and DZHK partner site Munich Heart Alliance, Ludwig-Maximilians-Universität, Munich, Germany (J.P.); Endokrinologikum Frankfurt, Frankfurt, Germany (A.M.); and Centre Hospitalier Universitaire de Québec Research Center, and Faculty of Medicine, Université Laval, Quebec, Canada (P.P.)
| | - Voahanginirina Randriamboavonjy
- From the Institute for Vascular Signaling, Centre for Molecular Medicine, and DZHK (German Centre for Cardiovascular Research) partner site Rhine-Main, Frankfurt, Germany (A.E., L.S., J.H., H.L., V.R., I.F.); Functional Proteomics, SFB 815 Core Unit, Goethe-University, Frankfurt, Germany (I.W.); Walter-Brendel-Centre of Experimental Medicine and DZHK partner site Munich Heart Alliance, Ludwig-Maximilians-Universität, Munich, Germany (J.P.); Endokrinologikum Frankfurt, Frankfurt, Germany (A.M.); and Centre Hospitalier Universitaire de Québec Research Center, and Faculty of Medicine, Université Laval, Quebec, Canada (P.P.)
| | - Ingrid Fleming
- From the Institute for Vascular Signaling, Centre for Molecular Medicine, and DZHK (German Centre for Cardiovascular Research) partner site Rhine-Main, Frankfurt, Germany (A.E., L.S., J.H., H.L., V.R., I.F.); Functional Proteomics, SFB 815 Core Unit, Goethe-University, Frankfurt, Germany (I.W.); Walter-Brendel-Centre of Experimental Medicine and DZHK partner site Munich Heart Alliance, Ludwig-Maximilians-Universität, Munich, Germany (J.P.); Endokrinologikum Frankfurt, Frankfurt, Germany (A.M.); and Centre Hospitalier Universitaire de Québec Research Center, and Faculty of Medicine, Université Laval, Quebec, Canada (P.P.).
| |
Collapse
|
63
|
Relationship between arterial atheromatous plaque morphology and platelet–associated miR–126 and miR–223 expressions. ASIAN PAC J TROP MED 2015; 8:309-14. [DOI: 10.1016/s1995-7645(14)60336-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
64
|
Volný O, Kašičková L, Coufalová D, Cimflová P, Novák J. microRNAs in Cerebrovascular Disease. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2015; 888:155-95. [PMID: 26663183 DOI: 10.1007/978-3-319-22671-2_9] [Citation(s) in RCA: 64] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Cardiovascular diseases are major causes of morbidity and mortality in developed countries. Cerebrovascular diseases, especially stroke, represent major burden of disability and economy impact. Major advances in primary and secondary prevention and therapy are needed in order to tackle this public health problem. Our better understanding of pathophysiology is essential in order to develop novel diagnostic and therapeutic tools and strategies. microRNAs are a family of important post-transcriptional regulators of gene expression and their involvement in the pathophysiology of cerebrovascular diseases has already been reported. Moreover, microRNAs may represent above-mentioned potential diagnostic and therapeutic tools in clinical practice. Within this chapter, we briefly describe basic epidemiology, aetiology and clinical manifestation of following cerebrovascular diseases: extracranial carotid atherosclerosis, acute stroke, intracranial aneurysms and cerebral arterio-venous malformations. Further, in each chapter, the current knowledge about the involvement of specific microRNAs and their potential use in clinical practice will be summarized. More specifically, within the subchapter "miRNAs in carotid atherosclerosis", general information about miRNA involvement in atherosclerosis will be described (miR-126, miR-17-92, miR-155 and others) with special emphasis put on miRNAs affecting carotid plaque progression and stability (e.g. miR-145, miR-146 or miR-217). In the subchapter "miRNAs in acute stroke", we will provide insight into recent knowledge from animal and human studies concerning miRNA profiling in acute stroke and their expression dynamics in brain tissue and extracellular fluids (roles of, e.g. let-7 family, miR-21, miR-29 family, miR-124, miR-145, miR-181 family, miR-210 and miR-223). Subchapters dealing with "miRNAs and AV malformations" and "miRNAs and intracranial aneurysms" will focus on miR-21, miR-26, miR-29 family and miR-143/145.
Collapse
Affiliation(s)
- Ondřej Volný
- Department of Neurology, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Pekarska 53, Brno, 656 91, Czech Republic. .,Department of Anatomy, Faculty of Medicine, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic. .,International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, Brno, 656 91, Czech Republic.
| | - Linda Kašičková
- Department of Neurology, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Pekarska 53, Brno, 656 91, Czech Republic. .,Department of Anatomy, Faculty of Medicine, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic.
| | - Dominika Coufalová
- Department of Anatomy, Faculty of Medicine, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic. .,International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, Brno, 656 91, Czech Republic.
| | - Petra Cimflová
- Department of Radiology, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Pekarska 53, Brno, 656 91, Czech Republic.
| | - Jan Novák
- 2nd Department of Internal Medicine, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Pekarska 53, Brno, 656 91, Czech Republic. .,Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, Brno, 62500, Czech Republic. .,Department of Physiology, Faculty of Medicine, Masaryk University, Brno, 62500, Czech Republic.
| |
Collapse
|
65
|
Liang D, Zhang Y, Han J, Wang W, Liu Y, Li J, Jiang X. Embryonic stem cell-derived pancreatic endoderm transplant with MCT1-suppressing miR-495 attenuates type II diabetes in mice. Endocr J 2015. [PMID: 26211669 DOI: 10.1507/endocrj.ej15-0186] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Type 2 diabetes mellitus (T2D) is a chronic metabolic disorder resulting from defects in both insulin secretion and insulin activity. The deficit and dysfunction of insulin secreting β-cells are signature symptoms of T2D. Additionally, in pancreatic β-cells, a small group of genes that are abundantly expressed in most other tissues is highly selectively repressed. Monocarboxylate transporter 1 (MCT1) is one of these genes. In this study, we identified an MCT1-suppressing microRNA (hsa-miR-495) and used this microRNA together with human embryonic stem cell (hESC) derived pancreatic endoderm (PE) cells transplanted into a high-fat diet induced T2D mouse model. Glucose metabolism significantly improved and other symptoms of T2D were attenuated after the procedure. Our findings support the potential for T2D treatment using the combination of microRNA and hESC differentiated PE cells.
Collapse
Affiliation(s)
- Dong Liang
- Tianjin First Center Hospital, NO.24 Fukang Road, Nankai District, Tianjin 300192, China
| | | | | | | | | | | | | |
Collapse
|
66
|
Chyrchel B, Totoń-Żurańska J, Kruszelnicka O, Chyrchel M, Mielecki W, Kołton-Wróż M, Wołkow P, Surdacki A. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report. Platelets 2014; 26:593-7. [PMID: 25350775 DOI: 10.3109/09537104.2014.974527] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Decreased plasma levels of microRNA-223 (miR-223), predominantly of platelet origin, were proposed as a surrogate marker of efficacy of antiplatelet therapy. However, higher on-treatment platelet reactivity was associated with lower plasma miR-223 in patients with coronary artery disease (CAD) on dual antiplatelet therapy (DAPT) including clopidogrel and aspirin. Our aim was to compare plasma miR-223 and platelet reactivity in CAD patients on DAPT with newer P2Y12 antagonists vs. clopidogrel. We studied 21 men with CAD admitted to our centre owing to a non-ST-elevation acute coronary syndrome, and with an uncomplicated hospital course. From the day of admission, the patients were receiving either clopidogrel (n = 11) or prasugrel/ticagrelor (n = 10) in addition to aspirin. Before discharge, miR-223 expression in plasma was estimated by quantitative polymerase chain reaction using the comparative Ct method relative to miR-16 as an endogenous control. Multiple electrode aggregometry was used to assess platelet aggregation in response to adenosine diphosphate (ADP). ADP-induced platelet reactivity was decreased in the patients treated with prasugrel or ticagrelor compared with those on clopidogrel (mean ± SD: 139 ± 71 vs. 313 ± 162 arbitrary units [AU]*min, p = 0.006), due to a more potent antiplatelet activity of the novel P2Y12 antagonists. Consequently, six out of seven patients in the lower tertile of the ADP-induced platelet aggregation were treated with the newer P2Y12 blockers, whereas six out of seven patients in the upper tertile were on clopidogrel. Plasma miR-223 was elevated with decreasing platelet reactivity (Spearman's rho = -0.52; p = 0.015 for trend), being significantly higher in the lower tertile of the ADP-induced platelet aggregation (median [range]: 1.06 [0.25-2.31]) vs. the upper tertile (0.20 [0.13-2.30]) (p = 0.04). In conclusion, our preliminary results argue against the notion of low plasma miR-223 as a marker of platelet responsiveness to DAPT. On the contrary, more potent platelet inhibition associated mainly with newer P2Y12 antagonists appears to coincide with higher miR-223 relative to the subjects with attenuated responsiveness to DAPT.
Collapse
Affiliation(s)
- Bernadeta Chyrchel
- 2nd Department of Cardiology, Jagiellonian University Medical College , Cracow , Poland
| | | | | | | | | | | | | | | |
Collapse
|